Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRPR | P30550 | 2/20 | 0.58 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.56 |
| ▸ | IL23R | Q5VWK5 | 12/20 | 0.56 |
| ▸ | PTH1R | Q03431 | 3/20 | 0.55 |
| ▸ | CCKAR | P32238 | 1/20 | 0.53 |
| ▸ | CCKBR | P32239 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29725771 | 0.96 | GRPR (0.59) | GRPRRXFP1IL23RPTH1R | |
| SCHEMBL31504096 | 0.94 | GRPR (0.59) | GRPRRXFP1IL23RPTH1RCCKAR | |
| SCHEMBL31174225 | 0.89 | PTH1R (0.66) | RXFP1IL23RPTH1RCCKBR | |
| SCHEMBL29816188 | 0.87 | IL23R (0.53) | GRPRIL23R | |
| SCHEMBL5509790 | 0.87 | IL23R (0.59) | RXFP1IL23RPTH1R | |
| SCHEMBL5509799 | 0.87 | IL23R (0.59) | RXFP1IL23RPTH1R | |
| SCHEMBL30198819 | 0.86 | ACE (0.54) | IL23R | |
| SCHEMBL29895786 | 0.86 | IL23R (0.52) | IL23RCCKARCCKBR | |
| SCHEMBL31694512 | 0.85 | PTH1R (0.71) | RXFP1IL23RPTH1RCCKBR | |
| SCHEMBL30130531 | 0.85 | IL23R (0.59) | IL23R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114588277-B | Construction method of polydopamine nano-particles loaded with temozolomide and Pep-1 | 江苏省苏北人民医院 | 2023-04-25 | — | — | CN | claimed |
| CN-114588277-B | Construction method of polydopamine nano-particles loaded with temozolomide and Pep-1 | 江苏省苏北人民医院 | 2023-04-25 | — | — | CN | disclosed |